Patent: 4,956,281
✉ Email this page to a colleague
Summary for Patent: 4,956,281
| Title: | DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3 |
| Abstract: | Polypeptides that bind to CD2, the receptor on the surface of T-lymphocytes. Most preferably, the polypeptides bind to CD2 on the surface of T-lymphocytes and inhibit adhesion between T-lymphocytes and target cells. DNA sequences that code on expression in appropriate unicellular hosts for those polypeptides. Methods of making and using those polypeptides in therapy and diagnosis. |
| Inventor(s): | Wallner; Barbara P. (Cambridge, MA), Springer; Timothy A. (Newton, MA), Hession; Catherine (South Weymouth, MA), Tizard; Richard (Cambridge, MA), Mattaliano; Robert (Newton, MA), Dustin; Michael L. (Boston, MA) |
| Assignee: | Biogen, Inc. (Cambridge, MA) Dana Farber Cancer Institute, Inc. (Boston, MA) |
| Application Number: | 07/057,615 |
| Patent Claims: | see list of patent claims |
Details for Patent 4,956,281
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Astellas Pharma Us, Inc. | AMEVIVE | alefacept | For Injection | 125036 | 01/30/2003 | ⤷ Try a Trial | 2039-03-29 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 4,956,281
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Austria | 176502 | ⤷ Try a Trial |
| Australia | 1955288 | ⤷ Try a Trial |
| Australia | 634464 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
